Skip to main content

Table 4 Post-baseline genotypic analysis through Week 48 in the 15 patients in the resistance analysis population

From: Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

Patient number

N[t]RTI backbone

Treatment cohort

Visit (week)

RAMs emerging*

Protease

Reverse transcriptase

1

Abacavir plus tenofovir

Naïve

24

None

None

2

Emtricitabine/tenofovir

Naïve

12

None

None

3

Emtricitabine/tenofovir

Naïve

48

I93I/L

I142L/P

4

Emtricitabine/tenofovir

Experienced

24

None

K22K/R

5

Emtricitabine/tenofovir

Naïve

36

R57R/K

M184V

6

Emtricitabine/tenofovir

Naïve

16

V32V/A, P39P/S

K122K/E, D123D/G/N/S, D177D/G, I178M

7

Emtricitabine/tenofovir

Naïve

48

None

D123D/E

8

Emtricitabine/tenofovir

Experienced

48

None

K122K/E, A272A/P

9

Emtricitabine/tenofovir

Experienced

12

I84I/V

E138T, T165A/E, R211R/K

10

Emtricitabine/tenofovir

Naïve

8

G86G/E

D123N

11

Emtricitabine/tenofovir plus zidovudine

Experienced

48

None

I195I/L

12

Abacavir plus tenofovir

Experienced

36

R41R/K

None

13

Emtricitabine/tenofovir

Naïve

48

V77V/I

E6E/K, E224E/Q, V245Q, T286T/A, V292V/I

14

Emtricitabine/tenofovir plus zidovudine

Experienced

48

None

E6E/D, V60I

15

Emtricitabine/tenofovir

Experienced

36

None

M184V

  1. *Compared to screening genotype – emerging primary resistance-associated mutations (RAMs) are shown in bold; N[t]RTI nucleoside/tide reverse transcriptase inhibitor.